Bamlanivimab is authorized for treatment of recently diagnosed, mild to moderate COVID-19 in high-risk patients. Authorization is based on Phase 2 clinical data that shows bamlanivimab reduces viral load, symptoms,… Read More
NOVEMBER 20, 2020 – VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced that the Company’s Compensation Committee granted the… Read More
Positive Data Updates Presented at the Society of Neuro-Oncology (SNO) Annual Meeting in Newly-Diagnosed, Recurrent, and First-Line GBM – In the Newly-Diagnosed Treatment Setting, Promising Median Progression-Free Survival of 10.0… Read More
Vancouver, BC – November 18, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM; TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and… Read More
VANCOUVER, British Columbia & BURLINGAME, Calif.–(BUSINESS WIRE)– Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics,and ALX Oncology Holdings Inc. (NASDAQ: ALXO), a clinical-stage immuno-oncology company developing therapies… Read More
